- Home
- RENB vs ASRT Comparison
RENB vs ASRT Comparison
Compare RENB & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- ASRT
- Stock Information
- Founded
- RENB 2011
- ASRT 1995
- Country
- RENB United States
- ASRT United States
- Employees
- RENB N/A
- ASRT N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- ASRT Health Care
- Exchange
- RENB Nasdaq
- ASRT Nasdaq
- Market Cap
- RENB 62.0M
- ASRT 57.9M
- IPO Year
- RENB N/A
- ASRT 1997
- Fundamental
- Price
- RENB $0.28
- ASRT $0.67
- Analyst Decision
- RENB
- ASRT Strong Buy
- Analyst Count
- RENB 0
- ASRT 2
- Target Price
- RENB N/A
- ASRT $3.25
- AVG Volume (30 Days)
- RENB 8.2M
- ASRT 245.9K
- Earning Date
- RENB 05-15-2025
- ASRT 08-06-2025
- Dividend Yield
- RENB N/A
- ASRT N/A
- EPS Growth
- RENB N/A
- ASRT N/A
- EPS
- RENB N/A
- ASRT N/A
- Revenue
- RENB N/A
- ASRT $119,001,000.00
- Revenue This Year
- RENB N/A
- ASRT N/A
- Revenue Next Year
- RENB N/A
- ASRT $11.91
- P/E Ratio
- RENB N/A
- ASRT N/A
- Revenue Growth
- RENB N/A
- ASRT N/A
- 52 Week Low
- RENB $0.27
- ASRT $0.51
- 52 Week High
- RENB $2.10
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- RENB 38.32
- ASRT 57.43
- Support Level
- RENB $0.33
- ASRT $0.63
- Resistance Level
- RENB $0.37
- ASRT $0.67
- Average True Range (ATR)
- RENB 0.04
- ASRT 0.03
- MACD
- RENB -0.01
- ASRT 0.00
- Stochastic Oscillator
- RENB 6.24
- ASRT 93.50
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.